Stocktoria
GENELUX Corp GNLX
GENELUX Corp (GNLX) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $8,000 at a -401812.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GNLX | GENELUX Corp | 2/9 | — | — | — |
| ASBP | Aspire Biopharma Holdings, Inc. | 2/9 | — | — | — |
| TCRT | Alaunos Therapeutics, Inc. | 2/9 | — | — | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 1/9 | -8.96 | — | -100% |
| XCUR | EXICURE, INC. | 1/9 | — | — | — |
| VTVT | vTv Therapeutics Inc. | 3/9 | -5.57 | — | — |
| VKTX | Viking Therapeutics, Inc. | 1/9 | 7.05 | — | — |
About GENELUX Corp
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
FAQ
Is GNLX financially healthy?
GENELUX Corp's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does GNLX pay a dividend?
No, GENELUX Corp does not currently pay a dividend.
How profitable is GNLX?
In FY2025, GENELUX Corp had a net margin of -401812.5% and a return on equity of -278.5%.
What is the analyst price target for GNLX?
The average Wall-Street price target for GENELUX Corp is $17.50, about 548.1% above the recent price, from 6 analysts.
Is GNLX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GENELUX Corp: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.